Cristina Larkin's most recent trade in Spero Therapeutics Inc was a trade of 53,190 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 1, 2022.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Spero Therapeutics Inc | Cristina Larkin | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 53,190 | 53,190 | - | - | Stock Option (Right to Buy) | |
Spero Therapeutics Inc | Cristina Larkin | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 38,014 | 63,581 (0%) | 0% | 0 | Common Stock | |
Spero Therapeutics Inc | Cristina Larkin | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Aug 2021 | 24,067 | 25,567 (0%) | 0% | 0 | Common Stock | |
Spero Therapeutics Inc | Cristina Larkin | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 57,432 | 57,432 | - | - | Stock Option (Right to Buy) | |
Spero Therapeutics Inc | Cristina Larkin | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2020 | 12,000 | 8,434 | - | - | Stock Option (Right to Buy) | |
Spero Therapeutics Inc | Cristina Larkin | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 19.00 per share. | 16 Dec 2020 | 12,000 | 1,500 (0%) | 0% | 19 | 228,000 | Common Stock |
Spero Therapeutics Inc | Cristina Larkin | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.90 per share. | 16 Dec 2020 | 12,000 | 13,500 (0%) | 0% | 5.9 | 70,800 | Common Stock |